21世纪原发性肝癌流行病学变迁
该研究基于GBD 2023数据库分析21世纪全球原发性肝癌负担,发现2000至2023年发病和死亡绝对数分别增加59.4%和55.8%,年龄标化率虽曾下降但约2020年反转回升。病毒性肝炎仍是主要病因但占比下降,乙肝和丙肝相关肝癌发病与死亡自2020年全球反弹,代谢功能障碍相关脂肪性肝病增长最快。
要点
- 2000至2023年全球肝癌发病和死亡绝对数分别增加59.4%和55.8%。
- 年龄标化发病率和死亡率约2020年反转回升,需持续监测。
- 乙肝和丙肝相关肝癌发病与死亡自2020年全球反弹。
核心结论
- 全球原发性肝癌负担持续上升,年龄标化率下降趋势约2020年反转,需持续公共卫生和临床干预。
研究设计与样本
- 基于GBD 2023数据库的分析,评估2000至2023年全球原发性肝癌发病和死亡趋势。
主要发现
- 2000至2023年原发性肝癌发病绝对数增加59.4%,死亡绝对数增加55.8%。
- 年龄标化发病率和死亡率从2000年下降,但约2020年反转回升。
- 病毒性肝炎仍是全球主要病因但占比下降,乙肝和丙肝相关肝癌发病与死亡自2020年全球反弹。
- 代谢功能障碍相关脂肪性肝病年龄调整发病率和死亡率增长最快且持续上升。
- 肝内胆管癌发病和死亡上升,需超越肝细胞癌的专门研究。
关键数值与推荐
- 病因地理差异:乙肝为主见于东亚和撒哈拉以南非洲,丙肝为主见于中东、北非和美洲,酒精相关病为主见于欧洲和澳大拉西亚。
临床怎么用
- 针对可预防和可治疗的肝病持续开展公共卫生和临床干预,以遏制未来肝癌负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
During the 21st century, the global burden of primary liver cancer has continued to rise, with the absolute numbers of incident cases and deaths increasing by 59.4% and 55.8%, respectively, between 2000 and 2023. Analysis of the GBD 2023 database shows that although age-standardised incidence and mortality rates declined from 2000, this favourable trend reversed around 2020, highlighting the need for continued surveillance. Viral hepatitis remains the leading cause of primary liver cancer worldwide, but its proportional contribution is decreasing. Notably, despite earlier gains from vaccination and antiviral therapies, hepatitis B- and hepatitis C-associated liver cancer incidence and mortality have rebounded globally since 2020. In contrast, metabolic dysfunction-associated steatotic liver disease has exhibited the fastest growth, with sustained increases in age-adjusted incidence and mortality across regions. Marked geographical variation persists in underlying aetiologies, with hepatitis B predominant in East Asia and Sub-Saharan Africa, hepatitis C in the Middle East, North Africa, the Americas, and alcohol-related disease in Europe and Australasia. Additionally, rising incidence and mortality of intrahepatic cholangiocarcinoma underscore the need for dedicated research beyond hepatocellular carcinoma. Collectively, these findings emphasise the urgency of sustained public health and clinical interventions targeting preventable and treatable liver diseases to curb future liver cancer burden.
引用
- Khan SA, Vithayathil M, Yip TCF, et al. The changing epidemiology of primary liver cancer in the 21st century. J Hepatol. 2026. PMID: 42542384. doi:10.1016/j.jhep.2026.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。